Radosław Mądry

4.7k total citations
85 papers, 814 citations indexed

About

Radosław Mądry is a scholar working on Reproductive Medicine, Oncology and Genetics. According to data from OpenAlex, Radosław Mądry has authored 85 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Reproductive Medicine, 42 papers in Oncology and 27 papers in Genetics. Recurrent topics in Radosław Mądry's work include Ovarian cancer diagnosis and treatment (45 papers), PARP inhibition in cancer therapy (27 papers) and BRCA gene mutations in cancer (23 papers). Radosław Mądry is often cited by papers focused on Ovarian cancer diagnosis and treatment (45 papers), PARP inhibition in cancer therapy (27 papers) and BRCA gene mutations in cancer (23 papers). Radosław Mądry collaborates with scholars based in Poland, Italy and United Kingdom. Radosław Mądry's co-authors include Mariusz Bidziński, Janina Markowska, David Cibula, Nicoletta Colombo, Marta Stelmach-Mardas, Marcin Mardas, Giovanni Scambia, Elizabeth Lowe, Joo‐Hyun Nam and Charles A. Leath and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Radosław Mądry

74 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Radosław Mądry Poland 16 513 377 221 131 95 85 814
Elizabeth K. Lee United States 13 309 0.6× 152 0.4× 205 0.9× 25 0.2× 120 1.3× 34 662
Paweł Knapp Poland 14 163 0.3× 130 0.3× 242 1.1× 39 0.3× 93 1.0× 67 629
Hiroyuki Furumoto Japan 15 181 0.4× 169 0.4× 258 1.2× 36 0.3× 199 2.1× 42 752
Rosekeila Simões Nomelini Brazil 14 235 0.5× 250 0.7× 95 0.4× 18 0.1× 183 1.9× 67 653
Takuya Ayabe Japan 12 112 0.2× 128 0.3× 173 0.8× 89 0.7× 75 0.8× 35 511
Masaaki Takai Japan 14 146 0.3× 72 0.2× 269 1.2× 75 0.6× 109 1.1× 31 620
Tomoko Uchiyama Japan 17 111 0.2× 98 0.3× 126 0.6× 59 0.5× 63 0.7× 68 684
Hitoo Nakano Japan 12 105 0.2× 482 1.3× 202 0.9× 88 0.7× 58 0.6× 15 835
N. H. Cho South Korea 7 297 0.6× 62 0.2× 271 1.2× 33 0.3× 40 0.4× 10 647
Laura Scaltriti Italy 8 225 0.4× 176 0.5× 79 0.4× 21 0.2× 23 0.2× 10 456

Countries citing papers authored by Radosław Mądry

Since Specialization
Citations

This map shows the geographic impact of Radosław Mądry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radosław Mądry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radosław Mądry more than expected).

Fields of papers citing papers by Radosław Mądry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radosław Mądry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radosław Mądry. The network helps show where Radosław Mądry may publish in the future.

Co-authorship network of co-authors of Radosław Mądry

This figure shows the co-authorship network connecting the top 25 collaborators of Radosław Mądry. A scholar is included among the top collaborators of Radosław Mądry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radosław Mądry. Radosław Mądry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
Pacholczak‐Madej, Renata, et al.. (2025). Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland. Frontiers in Immunology. 16. 1604826–1604826.
6.
7.
Ostrowska-Leśko, Marta, Radosław Mądry, & Marcin Bobiński. (2025). Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. Trials. 26(1). 325–325.
8.
Markowska, Anna, Anna Gryboś, Andrzej Marszałek, et al.. (2021). Expression of selected molecular factors in two types of endometrial cancer. Advances in Clinical and Experimental Medicine. 30(10). 1057–1064. 2 indexed citations
9.
Bodnar, Lubomir, Paweł Knapp, Jacek Jan Sznurkowski, et al.. (2019). Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer. European Journal of Gynaecological Oncology. 40(2). 236–241.
10.
Blecharz, Paweł, Radosław Mądry, & Marek Jasiówka. (2016). Treatment of advanced ovarian cancer with bevacizumab in Poland — a chance to improve survival still missed. Oncology in Clinical Practice. 12(5). 167–178. 1 indexed citations
11.
Mardas, Marcin, Marta Stelmach-Mardas, Kamil Zalewski, et al.. (2016). Influence of body weight changes on survival in patients undergoing chemotherapy for epithelial ovarian cancer.. PubMed. 20(10). 1986–92. 1 indexed citations
12.
Mardas, Marcin, Marta Stelmach-Mardas, & Radosław Mądry. (2016). Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival. Supportive Care in Cancer. 25(3). 795–800. 12 indexed citations
13.
Basta, Antoni, Mariusz Bidziński, Andrzej Bieńkiewicz, et al.. (2015). Rekomendacje Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka jajnika Wersja 2015.1. Via Medica Journals. 1(2). 83–93. 1 indexed citations
14.
Basta, Antoni, Mariusz Bidziński, Andrzej Bieńkiewicz, et al.. (2015). Recommendation of the Polish Society of Oncological Gynaecology on the diagnosis and treatment of epithelial ovarian cancer. Oncology in Clinical Practice. 11(5). 233–243. 10 indexed citations
15.
Jassem, Jacek, Renata Duchnowska, Andrzej Kawecki, et al.. (2014). Post-treatment surveillance in most common solid malignancies in adults. Oncology in Clinical Practice. 10(6). 290–313. 1 indexed citations
16.
Markowska, Janina, Jan Kornafel, Stefan Sajdak, et al.. (2013). Recommendations of Polish Gynecological Oncology Society concerning epithelial tumors of the ovary: ovarian cancer and borderline tumors. 11(1). 9–23. 3 indexed citations
17.
18.
Rzepecka, Iwona K., Lukasz M. Szafron, Agnieszka Styś, et al.. (2012). High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genetics. 205(3). 94–100. 19 indexed citations
19.
Bidziński, Mariusz, et al.. (2009). Pattern of failure in endometrial cancer patients. Ginekologia Polska. 80(9). 1 indexed citations
20.
Kupryjańczyk, Jolanta, Radosław Mądry, Joanna Plisiecka-Hałasa, et al.. (2004). TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. British Journal of Cancer. 91(11). 1916–1923. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth K. Lee Breakdown of academic impact, for papers by Paweł Knapp Breakdown of academic impact, for papers by Hiroyuki Furumoto Breakdown of academic impact, for papers by Rosekeila Simões Nomelini Breakdown of academic impact, for papers by Takuya Ayabe Breakdown of academic impact, for papers by Masaaki Takai Breakdown of academic impact, for papers by Tomoko Uchiyama Breakdown of academic impact, for papers by Hitoo Nakano Breakdown of academic impact, for papers by N. H. Cho Breakdown of academic impact, for papers by Laura Scaltriti
Rankless by CCL
2026